An interventional study of Test orthokeratology lens and Control orthokeratology lens in Myopia, sponsored by Menicon Co., Ltd.. Completed at 3 sites in Singapore. Open to participants aged 6 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment
A prospective, multicenter, randomized, controlled clinical trial of orthokeratology lens
The test product is the orthokeratology lens, and the control product is a commercially available orthokeratology lens. The number of enrolled subjects is 390, and clinical observation is performed for 12 months.
984 studies on the registry are indexed under Myopia; 210 are open to participants now.
This study's enrollment of 390 is above the median of 80 across 783 interventional studies indexed under Myopia.
Browse Myopia studies →Menicon Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
\<At screening>
(1) Those who are determined to be unable to obtain good centralized positioning even though changing strength (2) Pregnancy confirmed (3) Those who are difficult in continuing the clinical trial at investigator's discretion
Randomized to Treatment
Device: Test orthokeratology lens
Randomized to Control
Device: Control orthokeratology lens
Randomized to test orthokeratology lens worn during sleep every night
Randomized to control orthokeratology lens worn during sleep every night
Visual acuity
uncorrected visual acuity measured using logMAR chart
Time frame: 1 year
Axial length
axial eye length in millimeter measured by MYAH (Topcon) and IOL master (ZEISS)
Time frame: 1 year
Refraction
spherical and cylinder power in diopter for best corrected visual acuity measured subjectively
Time frame: 1 year
Adverse Events
Adverse events are classified into moderate, middle, or severe.
Time frame: 1 year
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menicon Co., Ltd.